Literature DB >> 9964

Assessment of drugs in schizophrenia. Basic trial design.

M Lader.   

Abstract

Clinical trials with major tranquilizers must take into account the clinical features of patients with schizophrenia and pharmacokinetic and pharmacodynamic properties of the drug. The objectives of the trial must be carefully defined so that appropriate selection criteria for patients, rating instruments and dosage schedules can be selected. It is useful to monitor physiological and biochemical actions of major tranquilizers as well as the clinical effects.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 9964      PMCID： PMC1428835          DOI： 10.1111/j.1365-2125.1976.tb03728.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  10 in total

1.  Sudden removal of tranquilizing drugs from chronic psychiatric patients.

Authors:  G W OLSON; D B PETERSON
Journal:  J Nerv Ment Dis       Date:  1960-09       Impact factor: 2.254

2.  Role of fluphenazine decanoate in lessening the burden of chronic schizophrenics on the community.

Authors:  B C Stevens
Journal:  Psychol Med       Date:  1973-05       Impact factor: 7.723

3.  Influence of selection of patients on results of clinical trials.

Authors:  J P Leff
Journal:  Br Med J       Date:  1973-10-20

4.  Life events and psychiatric disorders. 2. Nature of causal link.

Authors:  G W Brown; T O Harris; J Peto
Journal:  Psychol Med       Date:  1973-05       Impact factor: 7.723

5.  Trial of maintenance therapy in schizophrenia.

Authors:  J P Leff; J K Wing
Journal:  Br Med J       Date:  1971-09-11

6.  Life-events and psychiatric disorders. 1. Some methodological issues.

Authors:  G W Brown; F Sklair; T O Harris; J L Birley
Journal:  Psychol Med       Date:  1973-02       Impact factor: 7.723

7.  Integrating psychiatric research with clinical training: N=1.

Authors:  F T Melges
Journal:  J Nerv Ment Dis       Date:  1972-03       Impact factor: 2.254

8.  Clinical biostatistics. XIV. The purposes of prognostic stratification.

Authors:  A R Feinstein
Journal:  Clin Pharmacol Ther       Date:  1972 Mar-Apr       Impact factor: 6.875

9.  Physiologic and clinical effects of chlorpromazine and their relationship to plasma level.

Authors:  G Sakalis; S H Curry; G P Mould; M H Lader
Journal:  Clin Pharmacol Ther       Date:  1972 Nov-Dec       Impact factor: 6.875

10.  Riboflavine as an indicator of drug taking behaviour.

Authors:  I H Jones
Journal:  Med J Aust       Date:  1967-02-04       Impact factor: 7.738
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.